PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding dry eye syndrome
Types of dry eye syndrome
Risk factors for dry eye syndrome
Signs and symptoms
Causes of dry eye syndrome
Epidemiology
Diagnosis
Disease management
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Pipeline analysis
Cyclokat
Diquas
EBI-005
MIM-D3
Lifitegrast
RGN-259
EBI-005
EGP-437
PART 08: Market segmentation by sub-type of dry eye
PART 09: Market segmentation by drug type
Oral antibiotics
Eye drops
Eye inserts
Eye ointments
PART 10: Geographical segmentation
Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 16: Key vendor analysis
Alcon
Allergan
Otsuka Holdings
Santen Pharmaceuticals
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Regional prevalence of dry eye syndrome
Exhibit 03: Diagnosis of dry eye syndrome
Exhibit 04: Surgical options
Exhibit 05: Punctal plugs
Exhibit 06: Global dry eye syndrome market 2014-2019 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Market segmentation by sub-type of dry eye
Exhibit 09: Dry eye syndrome: pharmacologic therapy
Exhibit 10: Artificial tears: Different generations
Exhibit 11: Global dry eye syndrome market share 2014
Exhibit 12: Global dry eye syndrome: Key drivers
Exhibit 13: Impact of drivers
Exhibit 14: Global dry eye syndrome: Key challenges
Exhibit 15: Impact of drivers and challenges
Exhibit 16: Global dry eye syndrome: Emerging trends
Exhibit 17: Global dry eye syndrome market share analysis 2014
Exhibit 18: Alcon: Business strategy
Exhibit 19: Alcon: Distribution of sales by category 2014
Exhibit 20: Alcon: Region-wise sales distribution 2014 ($ millions)
Exhibit 21: Alcon: Region-wise sales distribution 2013 ($ millions)
Exhibit 22: Systane: Global sales 2011-2014 ($ millions)
Exhibit 23: Allergan: Business strategy
Exhibit 24: Eye care pharmaceuticals: Global sales 2011-2014 ($ millions)
Exhibit 25: Restasis: Global sales 2011-2014 ($ millions)
Exhibit 26: Santen Pharmaceuticals: Business strategy
Exhibit 27: Hyalein: Global sales 2011-2014 ($ millions)
Exhibit 28: Diquas: Global sales 2011-2014 ($ millions)
Exhibit 29: Prescription ophthalmics : Global sales 2011-2014 ($ millions)
Exhibit 30: Alcon: Business segmentation 2014
Exhibit 31: Allergan: Business segmentation by revenue 2014
Exhibit 32: Allergan: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 33: Allergan: Geographical segmentation by revenue 2014
Exhibit 34: Santen Pharmaceutical: Business/Product segmentation 2014 by revenue
【掲載企業】
Alcon, Allergan, Otsuka Holdings, Santen Pharmaceuticals, Acadia Pharmaceuticals, Aciex, Allostera Pharma, arGentis, Auven Therapeutics (Celtic), Bridge Pharma, Can-Fite, Cellzome
【資料のキーワード】
ドライアイ症候群（眼球乾燥症候群）、治療薬、パイプライン、医薬品
【調査方法】
一次資料による調査（業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など）及び二次資料による調査（Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど）
【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。
